Larry Goldstein to Cost-Benefit Analysis
This is a "connection" page, showing publications Larry Goldstein has written about Cost-Benefit Analysis.
Connection Strength
0.138
-
Screening for asymptomatic carotid artery stenosis: caveat emptor. Ann Intern Med. 2014 Sep 02; 161(5):370-1.
Score: 0.103
-
The Stroke P.O.R.T.: secondary and tertiary prevention of ischemic stroke. Stroke Prevention Patient Outcomes Research Team. Health Rep. 1994; 6(1):154-9.
Score: 0.025
-
An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000 Nov; 6(6):741-8.
Score: 0.010